We’ve identified three of the best cheap stocks to buy today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Price is important to us all, especially during tough economic times. That is true in all aspects of life, including investing.
Finding that gem stock – buying at a cheap price and enjoying the upside as it fulfills its potential and grows – is fundamental in the appeal of investing.
We’ve highlighted three stocks via our Stock Screener, which could be worth following. You can click on their ticker to find more comprehensive TipRanks data on their business model, earnings history and latest news.
Quad/Graphics (QUAD)
Quad/Graphics, Inc. provides marketing solutions worldwide. The company operates through United States Print and Related Services, and International segments. It offers printing services, such as retail inserts, publications, catalogs, special interest publications, journals, direct mail, directories, in-store marketing and promotion, packaging, newspapers, custom print products, and other commercial and specialty printed products; and paper procurement services.
According to TipRanks analysis, the stock’s price is currently $7.14 per share with a market cap of around $359 million. Based on 3 Wall Street analysts offering 12-month price targets for Quad/Graphics in the last 3 months, the average price target is $10.00 with a high forecast of $10.00 and a low forecast of $10.00. It has a 40.06% upside.
Sangamo Therapeutics (SGMO)
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients’ lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation.
According to TipRanks analysis, the stock price is $0.13 per share and has a market cap of almost $56 million. Based on 2 Wall Street analysts offering 12-month price targets for Sangamo Therapeutics in the last 3 months, the average price target is $6.00 with a high forecast of $10.00 and a low forecast of $2.00. It has an upside of 4,613.28%.
Enlivex (ENLV)
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.
According to TipRanks analysis, the stock price is $0.80 and it has a market cap of $201.6 million. Based on 1 Wall Street analyst offering a 12-month price target for Enlivex in the last 3 months, the average price target is $20.00 with a high forecast of $20.00 and a low forecast of $20.00. It has a 2,415.41% upside.
